Literature DB >> 9719512

The effects of protein farnesyltransferase inhibitors on trypanosomatids: inhibition of protein farnesylation and cell growth.

K Yokoyama1, P Trobridge, F S Buckner, J Scholten, K D Stuart, W C Van Voorhis, M H Gelb.   

Abstract

Attachment of the prenyl groups farnesyl and geranylgeranyl to specific eukaryotic cell proteins by protein prenyltransferases is required for the functioning of a number of cellular processes including signal transduction. In this study it was found that previously reported inhibitors of mammalian protein farnesyltransferase (PFT) [those that mimic the substrate farnesyl pyrophosphate and those that mimic the protein acceptor of the farnesyl group (CaaX mimetic)] inhibit in vitro farnesylation catalyzed by partially purified Trypanosoma brucei (T. brucei) PFT. The most potent PFT inhibitors at concentrations of 3-10 microM inhibit the growth of insect (procyclic) and bloodstream forms of T. brucei. One of the PFT inhibitors was found to block the incorporation of radiolabeled mevalonic acid (the precursor of prenyl groups) into specific T. brucei proteins. This study also shows that protein prenylation occurs in the protozoan parasites Trypanosoma cruzi (T. cruzi) and Leishmania mexicana (L. mexicana). The growth of T. cruzi intracellular form (amastigote) is also sensitive to PFT inhibitors, whereas the insect form (epimastigote) is considerably more resistant to inhibition of protein farnesylation. On the other hand, growth of 3T3 fibroblast cells (host cells for amastigote growth) was not affected by up to 100 microM PFT inhibitors. The growth of L. mexicana insect form (promastigote) is modestly inhibited by protein farnesyltransferase inhibitors. These results suggest the potential for the development of PFT inhibitors for treating trypanosomiasis and leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9719512     DOI: 10.1016/s0166-6851(98)00053-x

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  21 in total

1.  Characterization of farnesylated protein tyrosine phosphatase TcPRL-1 from Trypanosoma cruzi.

Authors:  Ileana C Cuevas; Peter Rohloff; Daniel O Sánchez; Roberto Docampo
Journal:  Eukaryot Cell       Date:  2005-09

2.  Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.

Authors:  Aurora Ortiz-Gómez; Carmen Jiménez; Antonio M Estévez; Juana Carrero-Lérida; Luis M Ruiz-Pérez; Dolores González-Pacanowska
Journal:  Eukaryot Cell       Date:  2006-07

3.  Atorvastatin is 10-fold more active in vitro than other statins against Plasmodium falciparum.

Authors:  Bruno Pradines; Marylin Torrentino-Madamet; Albin Fontaine; Maud Henry; Eric Baret; Joel Mosnier; Sébastien Briolant; Thierry Fusai; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

4.  Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei.

Authors:  F S Buckner; K Yokoyama; L Nguyen; A Grewal; H Erdjument-Bromage; P Tempst; C L Strickland; L Xiao; W C Van Voorhis; M H Gelb
Journal:  J Biol Chem       Date:  2000-07-21       Impact factor: 5.157

5.  Protein Lipidation: Occurrence, Mechanisms, Biological Functions, and Enabling Technologies.

Authors:  Hong Jiang; Xiaoyu Zhang; Xiao Chen; Pornpun Aramsangtienchai; Zhen Tong; Hening Lin
Journal:  Chem Rev       Date:  2018-01-02       Impact factor: 60.622

6.  Antileishmanial effect of mevastatin is due to interference with sterol metabolism.

Authors:  Neeradi Dinesh; Neelagiri Soumya; Sushma Singh
Journal:  Parasitol Res       Date:  2015-07-18       Impact factor: 2.289

7.  Protein geranylgeranyltransferase-I of Trypanosoma cruzi.

Authors:  Kohei Yokoyama; John R Gillespie; Wesley C Van Voorhis; Frederick S Buckner; Michael H Gelb
Journal:  Mol Biochem Parasitol       Date:  2007-10-02       Impact factor: 1.759

8.  Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum.

Authors:  Véronique Parquet; Maud Henry; Nathalie Wurtz; Jerome Dormoi; Sébastien Briolant; Marine Gil; Eric Baret; Rémy Amalvict; Christophe Rogier; Bruno Pradines
Journal:  Malar J       Date:  2010-05-25       Impact factor: 2.979

9.  Trypanosoma brucei prenylated-protein carboxyl methyltransferase prefers farnesylated substrates.

Authors:  Frederick S Buckner; David P Kateete; George W Lubega; Wesley C Van Voorhis; Kohei Yokoyama
Journal:  Biochem J       Date:  2002-11-01       Impact factor: 3.857

10.  Characterization and selective inhibition of myristoyl-CoA:protein N-myristoyltransferase from Trypanosoma brucei and Leishmania major.

Authors:  Chrysoula Panethymitaki; Paul W Bowyer; Helen P Price; Robin J Leatherbarrow; Katherine A Brown; Deborah F Smith
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.